Pila Pharma is currently in an intensive development phase with its flagship candidate XEN-D0501. Unlike the GLP-1 agonists that currently dominate the obesity market, XEN-D0501 is a TRPV1 inhibitor – a small molecule formulated as an oral tablet.
To support the company’s continued journey, Pila Pharma announced on Thursday that Professor Thomas Lutz from the University of Zurich is joining its Scientific Advisory Board.
Expertise in amylin and metabolic control
Professor Lutz is a renowned preclinical researcher who has spent decades studying the regulation of food intake. His work has focused particularly on amylin, a pancreatic hormone that plays a crucial role in metabolism, as well as its interactions with other key hormones like leptin and GLP-1.
This expertise is highly relevant in today’s landscape, where the next generation of obesity treatments is moving beyond simple GLP-1 agonism toward combination therapies involving amylin and other pathways.
CSO Dorte X. Gram comments on the appointment:
- I'm very pleased that Professor Lutz is now joining our Scientific Advisory Board bringing substantial knowledge and know-how within pre-clinical studies of obesity. […] I now really look forward to join forces with Thomas to unravel how XEN-D0501 may affect obesity in man, and in particular interpreting the results of PILA's upcoming two pre-clinical obesity studies in DIO and Zucker rats.
Eagerly awaiting proof-of-concept
The timing of the appointment is significant. Pila Pharma have announced they would conduct preclinical studies in obesity models (DIO and Zucker rats) to generate proof-of-concept data for XEN-D0501 in weight loss.
The market is eagerly awaiting these results, which the company has previously communicated are expected before their TO2 warrant which is due in February 2026. Positive data from these studies would be a major value inflection point, validating TRPV1 inhibition as a viable new mechanism of action for obesity treatment.
Targeting a gap in the market
While the obesity market is booming, driven by injectable peptides, there is a significant demand for effective oral alternatives that are scalable and patient-friendly.
Pila Pharma aims to fill this gap. If the upcoming preclinical data confirms the weight-loss potential of XEN-D0501, the company will be well-positioned with a differentiated, oral candidate in a market projected to be worth over USD 100 billion annually. With Professor Lutz on board, the company has now secured top-tier expertise to help navigate the translation of these preclinical findings into clinical strategy.
– New oral solutions will be critical to addressing the enormous consumer volumes globally for weight loss products. The obesity market, both the medical and the cosmetic segments, is projected to grow substantially in the next few years and pharma companies looking to enter these segments are especially interested in differentiated alternatives, Pila CEO Gustav H. Gram told BioStock in a recent interview.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.